Sangamo Therapeutics (SGMO) to Release Earnings on Monday

Key Points

• Sangamo will likely release Q4 2025 results before the market opens on Monday, March 16, with analysts expecting about $0.01 EPS and $40.25 million in revenue; an earnings call is scheduled for March 19 at 4:00 PM ET.
• The stock trades around $0.38 (50‑day/200‑day averages $0.41/$0.50) with a 52‑week range of $0.35–$1.06 and a market cap of roughly $127 million, reflecting a very low valuation and high volatility.
• Institutional investors own ~56.9% of the shares with several small recent buys, and analyst coverage is mixed (one Buy, two Hold, one Sell) leaving an average target of $4.33 and a consensus rating of "Hold."

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) will likely be issuing its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect the company to announce earnings of $0.01 per share and revenue of $40.25 million for the quarter. Individuals may review the information on the company's upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 19, 2026 at 4:00 PM ET.

Sangamo Therapeutics Price Performance

NASDAQ SGMO opened at $0.38 on Monday. The stock's fifty day moving average price is $0.41 and its 200 day moving average price is $0.50. Sangamo Therapeutics has a 1 year low of $0.35 and a 1 year high of $1.06. The company has a market cap of $127.03 million, a price-to-earnings ratio of -0.86 and a beta of 1.33.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Cetera Investment Advisers acquired a new position in Sangamo Therapeutics in the fourth quarter valued at approximately $31,000. XTX Topco Ltd acquired a new stake in shares of Sangamo Therapeutics during the 2nd quarter worth approximately $41,000. State of Wyoming purchased a new position in shares of Sangamo Therapeutics during the 4th quarter valued at approximately $47,000. Engineers Gate Manager LP increased its holdings in shares of Sangamo Therapeutics by 101.7% during the 2nd quarter. Engineers Gate Manager LP now owns 87,425 shares of the biopharmaceutical company's stock valued at $47,000 after purchasing an additional 44,078 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at $56,000. 56.92% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

SGMO has been the subject of a number of research reports. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Sangamo Therapeutics in a research report on Thursday, January 22nd. HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, February 10th. Finally, Wall Street Zen lowered Sangamo Therapeutics to a "strong sell" rating in a research report on Saturday, January 31st. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Sangamo Therapeutics presently has an average rating of "Hold" and an average target price of $4.33.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company's platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.